👤 Y Li

🔍 Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧬 Extraction
3991
Articles
2551
Name variants
Also published as: Xiaofeng Li, Jiajia Li, Jingwen Li, Zhaolun Li, Litao Li, Ruyi Li, Xiaocun Li, Jianyu Li, Wanxin Li, Jinsong Li, Xinzhi Li, Guanqiao Li, Ying-Lan Li, Zequn Li, Yulin Li, Shaojian Li, Guang-Xi Li, Yubo Li, Bugao Li, Mohan Li, Qingchao Li, Yan-Xue Li, Xikun Li, Enhong Li, Guobin Li, Hong-Tao Li, Xiangnan Li, Yong-Jun Li, Hang Li, Rongqing Li, Ziming Li, Xihao Li, Jing-Ming Li, Chang-Da Li, Meng-Yue Li, Yuanchang Li, DaZhuang Li, Xiao-Lin Li, Yicun Li, Jiajie Li, Zhao-Yang Li, Shunqin Li, Xinjia Li, K-L Li, Yaqiong Li, Bin Li, Yuan-hao Li, Jianhai Li, Peiwu Li, Youran Li, Yongmei Li, Changyu Li, Peilin Li, Ran Li, X Y Li, Chunshan Li, Ming Zhou Li, Yixiang Li, Ye Li, Guanglve Li, Z Li, Zili Li, Xinmei Li, Yihao Li, Liling Li, Qing Run Li, Wulan Li, Meng-Yang Li, Ziyun Li, Haoxian Li, Xiaozhao Li, Jun-Ying Li, Da-Lei Li, Xinhai Li, Yongjiang Li, Wanru Li, Jinming Li, Huihui Li, Wenhao Li, Qiankun Li, Kailong Li, Shisheng Li, Shengxu Li, Sai Li, Guangwen Li, Hua Li, Xiuli Li, Yulong Li, Dongmei Li, Ru-Hao Li, Lanzhou Li, Zhi-Peng Li, Tingsong Li, Binjun Li, Chen Li, Yawei Li, Jiayang Li, Zunjiang Li, Chao Bo Li, Minglong Li, Donghua Li, Wenzhe Li, Siming Li, Fengli Li, Song Li, Zihan Li, Hsin-Hua Li, Jin-Long Li, Hongxin Li, You Li, Dongfeng Li, Zhen-Yuan Li, Xueyang Li, Xuelin Li, Fa-Hui Li, Caiyu Li, Guangpu Li, Teng Li, Wen-Jie Li, Ang Li, Hegen Li, Zhizong Li, Lu-Yun Li, Peng Li, Shiyu Li, Bao Li, Yin Li, Cai-Hong Li, Fang Li, Jiuke Li, Miyang Li, Chen-Xi Li, Mingxu Li, Panlong Li, Changwei Li, Dejun Li, Biyu Li, Yufeng Li, Miaoxin Li, San-Feng Li, Yaoqi Li, Hu Li, Bei Li, Sha Li, W H Li, Jiaming Li, Jiyuan Li, Ya-Qiang Li, Rongkai Li, Yani Li, Xiushen Li, Xiaoqing Li, Jinlin Li, Linke Li, C Y Li, Shuaicheng Li, Thomas Li, Siting Li, Xuebiao Li, Yingyi Li, Yongnan Li, Maolin Li, Jiyang Li, Jinchen Li, Jin-Ping Li, Xuewen Li, Zhongxuan Li, R Li, Xianlong Li, Aixin Li, Linting Li, Zhong-Xin Li, Xuening Li, Enhao Li, Guang Li, Xiaoming Li, Shengliang Li, Yongli Li, Z-H Li, Baohong Li, Hujie Li, Yue-Ming Li, Shuyuan Li, Zhaohan Li, L Li, Alexander Li, Yuanmei Li, Yanwu Li, Hualing Li, Wen-juan Li, Sibing Li, Xining Li, Qinghe Li, Pilong Li, Yun-Peng Li, C X Li, Zonghua Li, Huanan Li, Liqin Li, Jingya Li, Youjun Li, Zheng-Dao Li, Miao X Li, Zhenshu Li, KeZhong Li, Heng-Zhen Li, Linying Li, Chu-Qiao Li, Fa-Hong Li, Changzheng Li, Yuhui Li, Wen-Ying Li, Wei Li, Yaokun Li, Shuanglong Li, Zhi-Gang Li, Yufan Li, Liangqian Li, Guanghui Li, Xiongfeng Li, Fei-feng Li, Letai Li, Ming Li, Kangli Li, Runwen Li, Wenbo Li, Yarong Li, Side Li, S E Li, Timmy Li, Weidong Li, Xin-Tao Li, Ruotong Li, Xiuzhen Li, Shuguang Li, Chuan-Hai Li, Lingxi Li, Jiezhen Li, Qiuya Li, Haitao Li, Tingting Li, Guanghua Li, Yufen Li, Zhongyu Li, Qin Li, Zhen-Yu Li, Deyu Li, Hansen Li, Annie Li, Wenge Li, Jinzhi Li, Xueren Li, Chun-Mei Li, Yijing Li, Kaifeng Li, Wen-Xing Li, Meng-Yao Li, Chung-I Li, Zhi-Bin Li, Junping Li, Qintong Li, Xiao Li, PeiQi Li, Naishi Li, Xiaobing Li, Liangdong Li, Xin-Ping Li, Yan Li, Han-Ni Li, Pan Li, Shengchao A Li, Jiaying Li, Jun-Jie Li, Ruonan Li, Cui-lan Li, Shuhao Li, Ruitong Li, Huiqiong Li, Guigang Li, Lucia M Li, Chunzhu Li, Suyan Li, Chengquan Li, Zexu Li, Gen-Lin Li, Dianjie Li, Zhilei Li, Junhui Li, Tiantian Li, Xue Cheng Li, Ya-Jun Li, Wenyong Li, Ding-Biao Li, Tianjun Li, Desen Li, Xiying Li, Yansong Li, Zihao Li, Weiyong Li, Xinyang Li, Fadi Li, Huawei Li, Yu-quan Li, Cui Li, Xiaoyong Li, Y L Li, Xueyi Li, Jingxiang Li, Jihua Li, Wenxue Li, Jingping Li, Zhiquan Li, Zeyu Li, Jianglin Li, Yingpu Li, Jing-Yao Li, Yan-Hua Li, Zongdi Li, Ming V Li, Shawn Shun-Cheng Li, Aowen Li, Xiao-Min Li, L K Li, Wan Jie Li, Ya-Ting Li, Aimin Li, Dongbiao Li, Tiehua Li, Keguo Li, Yuanfei Li, Longhui Li, Jing-Yi Li, Zhonghua Li, Guohong Li, Chunyi Li, Botao Li, Peiyun Li, L-Y Li, Xiuqi Li, Qinglan Li, Zhenhua Li, Zhengda Li, Haotong Li, Yue-Ting Li, Luhan Li, Da Li, Yuancong Li, Yuxiu Li, Tian Li, YiPing Li, Beibei Li, Demin Li, Haipeng Li, Chuan Li, Ze-An Li, Changhong Li, Jianmin Li, Minhui Li, Yvonne Li, Yu Li, Yiwei Li, Jiayuan Li, Xiangzhe Li, Zhichao Li, Siguang Li, Minglun Li, Yige Li, Chengqian Li, Weiye Li, Xue-Min Li, Kenneth Kai Wang Li, Dong-fei Li, Xiangchun Li, Chiyang Li, Chunlan Li, Hulun Li, Juan-Juan Li, Hailong Li, Hua-Zhong Li, Kun-Peng Li, Jiaomei Li, Haijun Li, Si Li, Xiangyun Li, Jing Li, Ji-Feng Li, Yingshuo Li, Wanqian Li, Baixing Li, Zijing Li, Dengke Li, Yuchuan Li, Wentao Li, Qingling Li, Rui-Han Li, Xuhong Li, Dong Li, Hongyun Li, Zhonggen Li, Xiong Li, Penghui Li, Xiaoxia Li, Dezhi Li, Huiting Li, Xiaolong Li, Linqing Li, Jiawei Li, Sheng-Jie Li, Defa Li, Ying-Qing Li, X L Li, Yuyan Li, Kawah Li, Xin-Jian Li, Guangxi Li, Yanhui Li, Zhenfei Li, Shupeng Li, Sha-Sha Li, Panyuan Li, Gang Li, Ziyu Li, Mengxuan Li, Hong-Wen Li, Zhuo Li, Han-Wei Li, Xiaojuan Li, Weina Li, Xiao-Hui Li, Dongnan Li, Huaiyuan Li, Rui-Fang Li, Jianzhong Li, Huaping Li, Ji-Liang Li, C H Li, Bohua Li, Bing Li, Pei-Ying Li, Huihuang Li, Yunmin Li, Shaobin Li, Yanying Li, Gui Lin Li, Ronald Li, Chenrui Li, Shi-Hong Li, Shilun Li, Xinyu Li, John Zhong Li, Song-Chao Li, Lujiao Li, Chenghong Li, Dengfeng Li, Nianfu Li, Baohua Li, N Li, Xiaotong Li, Chensheng Li, Ming-Qing Li, Yongxue Li, Bao-Shan Li, Jiao Li, Zhimei Li, Jun-Cheng Li, Yimeng Li, Jingming Li, Jinxia Li, De-Tao Li, Chunting Li, Shu Li, Julia Li, Chien-Feng Li, Huilan Li, Mei-Zhen Li, Xin-Ya Li, Zhengjie Li, Chunsheng Li, Yan-Yan Li, Liwei Li, Huijun Li, Chengyun Li, Chengjian Li, Ying-na Li, Guihua Li, Zhiyuan Li, Supeng Li, Lijun Li, Hening Li, Yiju Li, Yuanhe Li, Guangxiao Li, Fengxia Li, Xueqin Li, Peixin Li, Feng-Feng Li, Zu-Ling Li, Jialing Li, Xin Li, Yunjiu Li, Zonghong Li, Dayong Li, Ningyan Li, Lingjiang Li, Yuhan Li, Zhenghui Li, Fuyuan Li, Ailing Li, H-F Li, Chaochen Li, Chunxia Li, Zhen-Li Li, Tengyan Li, Xianlu Li, Jiaqi Li, Jiabei Li, Zhengying Li, Yali Li, Zhaoshui Li, Yu-Hui Li, Wenjing Li, Jingshu Li, Chuang Li, Jiajun Li, Can Li, Zhe Li, Han-Bo Li, Stephen Li, Shuangding Li, Zengyang Li, Kaiyuan Li, Mangmang Li, Chunyan Li, Runzhen Li, Xiaopeng Li, Xi-Hai Li, Anan Li, MengGe Li, Xuezhong Li, Luying Li, Jiajv Li, Pei-Lin Li, Xiaoquan Li, Wan-Xin Li, Ning Li, Ruobing Li, Yanxi Li, Xia Li, Yongjing Li, Meitao Li, Ziqiang Li, Huayao Li, Wen-Xi Li, Shenghao Li, Huixue Li, Jiqing Li, Boxuan Li, Hehua Li, Yucheng Li, Qingyuan Li, Yongqi Li, Fengqi Li, Yuqing Li, Zhigang Li, Guiyang Li, Guo-Qiang Li, Dujuan Li, Yanbo Li, Yuying Li, Shaofei Li, Sanqiang Li, Shaoguang Li, Hongyu Li, Min-Rui Li, Guangping Li, Shuqiang Li, Dan C Li, Huashun Li, Jinxin Li, Ganggang Li, Xinrong Li, Haoqi Li, Yayu Li, Handong Li, Huaixing Li, Yan-Nan Li, Xianglong Li, Minyue Li, Hong-Mei Li, Jing-Jing Li, Songhan Li, Mengxia Li, Conglin Li, Jutang Li, Qingli Li, Yongxiang Li, Miao Li, Songlin Li, Qilong Li, Dijie Li, Chenyu Li, Yizhe Li, Ke Li, Yan Bing Li, Jiani Li, Lianjian Li, Yiliang Li, Zhen-Hua Li, Chuan-Yun Li, Xinpeng Li, Hongxing Li, Wanyi Li, Gaoyuan Li, Youming Li, Mi Li, Dong-Yun Li, Qingrun Li, Guo Li, Jingxia Li, Xiu-Ling Li, Fuhai Li, Ruijia Li, Shuangfei Li, Yumiao Li, Fengfeng Li, Jiexi Li, Qinggang Li, Huixia Li, Kecheng Li, Xiangjun Li, Junxu Li, Xingye Li, Junya Li, Jiang Li, Huiying Li, Shengxian Li, Qingyang Li, Yuxi Li, Chenxuan Li, Xiao-Dong Li, Xinghuan Li, Zhaoping Li, Xingyu Li, Zhenlu Li, Xiaolei Li, Wenying Li, Huilong Li, Xiao-Gang Li, Honghui Li, Zhenhui Li, Cheung Li, Xuelian Li, Zhenming Li, Shu-Fen Li, Chunjun Li, Changyan Li, Mulin Jun Li, Yinghua Li, Shangjia Li, Yanjie Li, Jingjing Li, Suhong Li, Xinping Li, Chaoying Li, Siyu Li, Qiu Li, Juanjuan Li, Guangzhen Li, Xiangyan Li, Kunlun Li, Shiyun Li, Xiaoyu Li, Yaobo Li, Shiquan Li, Mei Li, Xuewang Li, Xiangdong Li, Jifang Li, Zhenjia Li, Wan Li, Manjiang Li, Zhizhong Li, Ding Yang Li, Xiao-Li Li, Xiaoya Li, Shan Li, Shitao Li, Zehan Li, Lijia Li, Chunqiong Li, Huiliang Li, Junjun Li, Chenlong Li, Shujin Li, Hui-Long Li, Zhao-Cong Li, Zhi-Wei Li, Wenxi Li, Weining Li, Wu-Jun Li, Chang-hai Li, Bin-Kui Li, Yumao Li, Yuqiu Li, Honglian Li, Xue-Yan Li, Ya-Zhou Li, Yuan-Yuan Li, Xiang-Jun Li, Hongyi Li, Chia Li, Y X Li, Yunyun Li, Zhen-Jia Li, Fu-Rong Li, Honghua Li, Lanjuan Li, Qiuxuan Li, Man-Zhi Li, Xiancheng Li, Yanmei Li, De-Jun Li, Keqing Li, Junxian Li, Zhihua Li, Shuwen Li, Danxi Li, Saijuan Li, Minqi Li, Lingjun Li, Mimi Li, Deheng Li, Si-Xing Li, Yingjie Li, Yaodong Li, Shigang Li, Yuan-Hai Li, Lujie Li, Minghao Li, Gao-Fei Li, Minle Li, Meifen Li, Yifeng Li, Le-Le Li, Huanqing Li, Ziwen Li, Yuhang Li, Yongqiu Li, Pu-Yu Li, Jianhua Li, Chanjuan Li, Nan-Nan Li, Lan-Lan Li, Hongming Li, Yanchuan Li, Shuang Li, Lingyi Li, Wanting Li, Bai-Qiang Li, Gong-Hua Li, Zhengyu Li, Chunmiao Li, Jiong-Ming Li, Yongqiang Li, Linsheng Li, Weiguang Li, Mingyao Li, Guoqing Li, Ze Li, Xiaomeng Li, R H L Li, Yuanze Li, Yunqi Li, Yuandong Li, Guisen Li, Jinglin Li, Dongyang Li, Mingfang Li, Honglong Li, Hanmei Li, Chenmeng Li, Changcheng Li, Shiyang Li, Shiyue Li, Hanbo Li, Jianing Li, Dingshan Li, Yinggao Li, Linlin Li, Xinsheng Li, Jin-Wei Li, Jin-Jiang Li, Cheng-Tian Li, Zhi-Xing Li, Chang Li, Yaxi Li, Ming-Han Li, Wei-Ming Li, Wenchao Li, Guangyan Li, Xuesong Li, Zhaosha Li, Jiwei Li, Yongzhen Li, Chun-Quan Li, Weifeng Li, Tao Li, Sichen Li, Wenhui Li, Xiankai Li, Qingsheng Li, Yaxuan Li, Liangji Li, Lixiang Li, Tian-wang Li, Yuchan Li, Jiaxi Li, Yalin Li, Jin-Liang Li, Pei-Zhi Li, Xiaoqiong Li, You Ran Li, Guanyu Li, Jinlan Li, Yixiao Li, Huizi Li, Jianping Li, Kathy H Li, Yun-Lin Li, Yadong Li, Yuhua Li, Sujing Li, Xuri Li, Wenzhuo Li, Deqiang Li, Caixia Li, Zipeng Li, Mingyue Li, Hongli Li, Mengqiu Li, Yun Li, Ling-Ling Li, Yanfeng Li, Yaqin Li, Yu-He Li, Shasha Li, S-C Li, Xi Li, Siyi Li, Minmin Li, Manna Li, Chengwen Li, Dawei Li, Shu-Feng Li, Haojing Li, Xun Li, Ming-Jiang Li, Zhiyu Li, Sitao Li, Ziyang Li, Yaochen Li, Qian Li, Tinghua Li, Wenyang Li, Bohao Li, Zhenfen Li, Shuo Li, Wenming Li, Mingxuan Li, Si-Ying Li, Xinyi Li, Jenny J Li, Xue-zhi Li, Anqi Li, Bingsong Li, Shuai Li, Xiaoju Li, Ting Li, Xiaonan Li, Zhenyu Li, Duan Li, Xiang-Yu Li, Lei Li, Hongde Li, Fengqing Li, Na Li, Xunjia Li, Yanchang Li, Huibo Li, Ruixia Li, Nanzhen Li, Chuanfang Li, Bingjie Li, Hongxue Li, Pengsong Li, Ruotian Li, Xiaojing Li, Xinlin Li, Zong-Xue Li, Chunya Li, En-Min Li, Yan Ning Li, Honglin Li, Yu-Ying Li, Jinhua Li, Min-jun Li, Yuanheng Li, Qian-Qian Li, Chunxiao Li, Wenli Li, Shijun Li, Mengze Li, Kuan Li, Baoguang Li, Kaiwei Li, Jie-Shou Li, Zimeng Li, Mengmeng Li, W-B Li, Huangyuan Li, Lili Li, Binkui Li, Junxin Li, Yu-Sheng Li, Wei-Jun Li, Guoyan Li, Fei-Lin Li, Junjie Li, Nuomin Li, Shanglai Li, Shulin Li, Yanyan Li, Yue Li, Taibo Li, Junqin Li, Xueying Li, JunBo Li, Zhongcai Li, Jun-Ru Li, Xiaoqi Li, Zhaobing Li, Xiucui Li, Linxin Li, Haihua Li, Yu-Lin Li, Jen-Ming Li, Tsai-Kun Li, Chen-Chen Li, Shujing Li, Hongquan Li, Chuan F Li, Mengyun Li, Mingna Li, Yanxiang Li, Lanlan Li, Moyi Li, Xiyun Li, Yi-Wen Li, Shihong Li, Huifeng Li, Rulin Li, Ya-Pei Li, Lijuan Li, Shengbin Li, Yuanhong Li, Zhongjie Li, Zhenbei Li, Jingyu Li, Xuewei Li, Long Li, Shuangshuang Li, Wenjia Li, Min-Dian Li, Xiatian Li, Ding-Jian Li, Hongwei Li, Danni Li, Yangxue Li, Xiao-Qiang Li, Chengnan Li, Chuanyin Li, Min Li, Zhenzhou Li, Yiqiang Li, Pengyang Li, Kun-Xin Li, Xiawei Li, Binglan Li, Zesong Li, Yutong Li, Xiangpan Li, Mingfei Li, Shuwei Li, Yingnan Li, Ge Li, Mingdan Li, Xihe Li, Xinzhong Li, Jianfeng Li, Chenyao Li, Jun-Yan Li, Dexiong Li, Rongsong Li, Boru Li, Yinxiong Li, Ruixue Li, Zemin Li, Jixi Li, Chris Li, Jicheng Li, Hong-Yu Li, Chuanning Li, Weijian Li, Changhui Li, Jiafei Li, Yingying Li, Gaizhi Li, Chien-Hsiu Li, Xiangcheng Li, Siqi Li, Dechao Li, Chunxing Li, Wenxia Li, Guoxiang Li, Ziru Li, Qiao-Xin Li, Huang Li, Shu-Fang Li, Qiusheng Li, Man Li, Juxue Li, Weiqin Li, Xinming Li, Huayin Li, Xiao-yu Li, Jianyi Li, Yongjun Li, Mengyang Li, Guo-Jian Li, Guowei Li, Chenglong Li, Xingya Li, Gongda Li, Nan Li, Wei-Ping Li, Yajun Li, Yipeng Li, Mingxing Li, Nanjun Li, Xin-Yu Li, Chunyu Li, P H Li, Jinwei Li, Xuhua Li, Yu-Xiang Li, Ranran Li, Suping Li, Long Shan Li, Yanze Li, Jason Li, Xiao-Feng Li, Monica M Li, Fengjuan Li, W Li, Xianlun Li, Hainan Li, Qi Li, Yutian Li, Xiaoli Li, Xiliang Li, Shuangmei Li, Ying-Bo Li, Fei Li, Xionghui Li, Duanbin Li, Maogui Li, Dan Li, Sumei Li, Hongmei Li, Kang Li, Peilong Li, Yinghao Li, Xu-Wei Li, Mengsen Li, Lirong Li, Wenhong Li, Quanpeng Li, Audrey Li, Yijian Li, Yajiao Li, Guang Y Li, Xianyong Li, Qilan Li, Shilan Li, Qiuhong Li, Zongyun Li, Xiao-Yun Li, Guang-Li Li, Cheng-Lin Li, Bang-Yan Li, Enxiao Li, Jianrui Li, Yousheng Li, Guohua Li, Wen-Ting Li, Kezhen Li, Xingxing Li, Guoping Li, Ellen Li, A Li, Simin Li, Xue-Nan Li, Weiguo Li, Yijie Li, Xiaoying Li, Shengsheng Li, Suwei Li, Shuyu D Li, Ruiwen Li, Jiandong Li, Fangyong Li, Hong Li, Binru Li, Yuqi Li, Zihua Li, Yuchao Li, Hanlu Li, Xue-Peng Li, Jianang Li, Qing Li, Jiaping Li, Sheng-Tien Li, Yazhou Li, Shihao Li, Jun-Ling Li, Caesar Z Li, Feng Li, Weiyang Li, Lang Li, Peihong Li, Jin-Mei Li, Lisha Li, Feifei Li, Kejuan Li, Qinghong Li, Qiqiong Li, Cuicui Li, Xinxiu Li, Kaibo Li, Chongyi Li, Yi-Ying Li, Hanbing Li, Meng-Hua Li, Shaodan Li, Yongzheng Li, J T Li, Da-Hong Li, Xiao-mei Li, Jiejie Li, Ruihuan Li, Xiangwei Li, Baiqiang Li, Ziliang Li, Yaoyao Li, Mo Li, Yueguo Li, Zheng Li, Donghe Li, Ming-Hao Li, Congfa Li, Wenrui Li, Hongsen Li, Yong Li, Xiuling Li, Menghua Li, Jingqi Li, Ka Li, Kaixin Li, Fuping Li, Zhiyong Li, Jianbo Li, Xing-Wang Li, Chong Li, Xiao-Kang Li, Hanqi Li, Fugen Li, Yangyang Li, Yuwei Li, Dongfang Li, Xiaochen Li, Zizhuo Li, Zhuorong Li, X-H Li, Xianrui Li, Lan-Juan Li, Dong Sheng Li, Zhigao Li, Chenlin Li, Zihui Li, Xiaoxiao Li, Guoli Li, Le-Ying Li, Pengcui Li, Huanqiu Li, Bing-Heng Li, Xiaoman Li, Zhan Li, Weisong Li, Xinglong Li, Xiaohong Li, Xiaozhen Li, Yuan Hao Li, Jianchun Li, Wenxiang Li, Zhaoliang Li, Guo-Ping Li, Zhiyang Li, Cunxi Li, Jinhui Li, Zhifei Li, Ying Li, Yanshu Li, Jianlin Li, Yuanyou Li, Chongyang Li, Yumin Li, Wanyan Li, Longyu Li, Jinku Li, Guiying Li, X B Li, Changgui Li, Zhisheng Li, Cuiling Li, Xuekun Li, Yuguang Li, Wenke Li, Jianguo Li, Jiayi Li, En Li, Ximei Li, Shaoyong Li, Kai-Wen Li, Suwen Li, Peihua Li, Chang-Ping Li, Guangda Li, Guandu Li, Yixue Li, Junfeng Li, Xin-Chang Li, Jieming Li, Kongdong Li, Yue-Ying Li, Chunhui Li, Peiyu Li, Tongyao Li, Lian Li, Linfeng Li, Xinmiao Li, Yuzhe Li, Chenyang Li, Jiacheng Li, Chang-Yan Li, Xiaohua Li, Qifang Li, Vivian Li, Duanxiang Li, Xiaolin Li, Meiting Li, Justin Li, Xue-Er Li, Zhuangzhuang Li, Xiaohui Li, Hongchang Li, Cang Li, Xuepeng Li, Mingjiang Li, Youwei Li, Ronggui Li, Xingwang Li, Tiange Li, Yongjia Li, Dacheng Li, Xinmin Li, Zongyu Li, Luquan Li, Jianyong Li, Guoxing Li, Shujie Li, Zongchao Li, Yanbin Li, Jia Li, Shiliang Li, Haimin Li, Qinrui Li, Sheng-Qing Li, Yiming Li, Lingjie Li, Xiao-Tong Li, Tie Li, Yiwen Li, Baoqi Li, Wei-Bo Li, Leyao Li, Xiaoyi Li, Liyan Li, Xiao-Qin Li, Xiaokun Li, Xinke Li, Ming-Wei Li, Minzhe Li, Wenfeng Li, Jiajing Li, Karen Li, Yanlin Li, X Li, Liao-Yuan Li, Meifang Li, Yanjing Li, Yongkai Li, Maosheng Li, Ju-Rong Li, Shibo Li, Jin Li, Hangwen Li, Li-Na Li, Hengguo Li, An-Qi Li, Xuehua Li, Hui Li, AnHai Li, Chenli Li, Rumei Li, Zhengrui Li, Fangqi Li, Xiaoguang Li, Xian Li, Danjie Li, Yan-Yu Li, Vivian S W Li, Lipeng Li, Qinghua Li, Qinqin Li, Leilei Li, Defu Li, Ranchang Li, Lianyong Li, Amy Li, Zhou Li, Q Li, Haoyu Li, Xiaoyao Li, M-J Li, Jiao-Jiao Li, Rongling Li, Zhu Li, Tong-Ruei Li, Bizhi Li, Cheng-Wei Li, Wenwen Li, Guangqiang Li, Jian'an Li, Ben Li, Sichong Li, Wenyi Li, Yingxia Li, Qing-Min Li, Meiyan Li, Yonghe Li, Yun-Da Li, Xinwei Li, Shunhua Li, Yu-I Li, Mingxi Li, Jian-Qiang Li, Yingrui Li, Chenfeng Li, Qionghua Li, Guo-Li Li, Xingchen Li, Ziqi Li, Shen Li, Tianjiao Li, Shufen Li, Gui-Rong Li, Yunfeng Li, Yunpeng Li, Yueqi Li, Qiong Li, Xiao-Guang Li, Jiali Li, Zhencheng Li, Qiufeng Li, Songyu Li, Xu Li, Pinghua Li, Shi-Fang Li, Shude Li, Zhibin Li, Yaxiong Li, Zhenli Li, Qing-Fang Li, Yunxiao Li, Rosa J W Li, Hsin-Yun Li, Shengwen Li, Gui-Bo Li, XiaoQiu Li, Xueer Li, Zhi Li, Zhankui Li, Zihai Li, Yue-Jia Li, Haihong Li, Peifen Li, Taixu Li, Mingzhou Li, Jiejing Li, Meng-Miao Li, Meiying Li, Chunlian Li, Meng Li, Zhijie Li, Cun Li, Huimin Li, T Li, Ruifang Li, Xiao-xu Li, Man-Xiang Li, Yinghui Li, Cong Li, Chengbin Li, Feilong Li, Yuping Li, Sin-Lun Li, Mengfan Li, Weiling Li, Jie Li, Shiyan Li, G Li, Lianbing Li, Yanchun Li, Xuze Li, Zhi-Yong Li, Yukun Li, Wenjian Li, Jialin Li, He Li, Bichun Li, Xiong Bing Li, Hanqin Li, Qingjie Li, Wen Lan Li, Guoge Li, Han Li, Wen-Wen Li, Keying Li, Yutang Li, Minze Li, Xingcheng Li, Wanshun Li, Congxin Li, Hankun Li, Hongling Li, Xiangrui Li, Chaojie Li, Michelle Li, Caolong Li, Zhifan Li, J Li, Zhi-Jian Li, Jianwei Li, Yan-Guang Li, Jiexin Li, Hongyan Li, Ji-Min Li, Zhen-Xi Li, Guangdi Li, Peipei Li, Tian-Yi Li, Xiaxia Li, Nien Li, Yuefeng Li, Zhihao Li, Peiyuan Li, Yao Li, Zheyun Li, Tiansen Li, Chi-Yuan Li, Xiangfei Li, Xue Li, Zhonglin Li, Fen Li, Lin Li, Jieshou Li, Chenjie Li, Jinfang Li, Roger Li, Yanming Li, Hong-Lan Li, Mengqing Li, S L Li, Ben-Shang Li, Xionghao Li, Ming-Kai Li, Shunqing Li, Lan Li, Menglu Li, Huiqing Li, Yanwei Li, Yantao Li, Chien-Te Li, Wenyan Li, Xiaoheng Li, Zeyuan Li, Yongle Li, Ruolin Li, Hongqin Li, Zhenhao Li, Jonathan Z Li, Haying Li, Shao-Dan Li, Yong-Liang Li, Muzi Li, Gen Li, Dong-Ling Li, M Li, Chenwen Li, Jiehan Li, Yong-Jian Li, Le Li, Hongguo Li, Chenxin Li, Yongsen Li, Qingyun Li, Pengyu Li, Si-Wei Li, Ai-Qin Li, Zichao Li, Manru Li, Caili Li, Yingxi Li, Yuqian Li, Wei-Dong Li, Guannan Li, Cien Li, Qingyu Li, Xijing Li, Jingshang Li, Xingyuan Li, Dehua Li, Wenlong Li, Ya-Feng Li, Yanjiao Li, Jia-Huan Li, Yuna Li, Xudong Li, Guoxi Li, Xingfang Li, Shugang Li, Shengli Li, Jisheng Li, Rongyao Li, Xuan Li, Yongze Li, Ru Li, Yongxin Li, Lu Li, Jiangya Li, Yiche Li, Yilang Li, Zhuo-Rong Li, Bingbing Li, Qinglin Li, Runzhi Li, Yunshen Li, Jingchun Li, Qi-Jing Li, Hexin Li, H J Li, Yanping Li, Zhenyan Li, Ji Xia Li, Meizi Li, Yu-Ye Li, Qing-Wei Li, Yuezheng Li, Qiang Li, Hsiao-Hui Li, Zhengnan Li, L I Li, Jianglong Li, Hongzheng Li, Laiqing Li, Ningyang Li, Zhongxia Li, Guangquan Li, Xiaozheng Li, Hui-Jun Li, Shun Li, Xuefei Li, Guojun Li, Senlin Li, Hung Li, Jinping Li, Huili Li, Sainan Li, Jinghui Li, Zulong Li, Chengsi Li, P Li, Hongzhe K Li, Fulun Li, Xiao-Qiu Li, Jiejia Li, Yonghao Li, Mingli Li, Yehong Li, Zhihui Li, Yi-Yang Li, Fujun Li, Pei Li, Quanshun Li, Yongping Li, Liguo Li, Ni Li, Weimin Li, Mingxia Li, Xue-Hua Li, M V Li, Luxuan Li, Qiang-Ming Li, Yakui Li, Huafu Li, Xinye Li, Shichao Li, Gan Li, Chunliang Li, Ruiyang Li, Dapei Li, Zejian Li, Chun Li, Lihong Li, Jianan Li, Haixia Li, Wenfang Li, Sung-Chou Li, Xiangling Li, Lianhong Li, Jingmei Li, Ao Li, Yitong Li, Siwen Li, Yanlong Li, Cheng Li, Kui Li, Zhao Li, Tiegang Li, Yunxu Li, Shuang-Ling Li, Zhong Li, Xiao-Long Li, Hung-Yuan Li, Xiaofei Li, Xuanfei Li, Zilin Li, Zhang Li, Jianxin Li, Mingqiang Li, H Li, Xiaojiao Li, Dongliang Li, Chenxiao Li, Yinzhen Li, Hongjia Li, Xiao-Jing Li, Li-Min Li, Yunsheng Li, Xiangqi Li, Jian Li, Y H Li, Jia-Peng Li, Baichuan Li, Daoyuan Li, Haibo Li, Wenqi Li, Zhenzhe Li, Jian-Mei Li, Xiao-Jun Li, Kaimi Li, Yan-Hong Li, Peiran Li, Shi Li, Xueling Li, Qiao Li, Yi-Yun Li, Xiao-Cheng Li, Conghui Li, Xiaoxiong Li, Yike Li, Wanni Li, Yihan Li, Chitao Li, Haiyang Li, Jiayu Li, Xiaobai Li, Junsheng Li, Pingping Li, Mingquan Li, Wen-Ya Li, Suran Li, Yunlun Li, Rongxia Li, Yuanfang Li, Yingqin Li, Guoqin Li, Qiner Li, Huiqin Li, Shanhang Li, Jiafang Li, Han-Bing Li, Chunlin Li, Zongzhe Li, Yikang Li, Jisen Li, Si-Yuan Li, Caihong Li, Hongmin Li, Peng Peng Li, Yajing Li, Guanglu Li, Kenli Li, Benyi Li, Yuquan Li, Xiushi Li, Hongzhi Li, Jian-Jun Li, Dongmin Li, Fengyi Li, Yanling Li, Chengxin Li, Juanni Li, Xiaojiaoyang Li, C Li, Jian-Shuang Li, Xinxin Li, You-Mei Li, Chenglan Li, Dazhi Li, Yubin Li, Beixu Li, Yuhong Li, Di Li, Guiyuan Li, Fengqiao Li, Yanbing Li, Suk-Yee Li, Yuanyuan Li, Jufang Li, Shengjie Li, Xiaona Li, Shanyi Li, Hongbo Li, Chih-Chi Li, Xinhui Li, Zecai Li, Qipei Li, Xiaoning Li, Jun Li, Minghua Li, Xiyue Li, Tianchang Li, Zhuoran Li, Hongru Li, Shiqi Li, Mei-Ya Li, Wuyan Li, Mingzhe Li, Yi-Ling Li, Hongjuan Li, Yingjian Li, Zhirong Li, Wang Li, Mingyang Li, Weijun Li, Boyang Li, Senmao Li, Cai Li, Mingjie Li, Ling-Jie Li, Hong-Chun Li, Jingcheng Li, Ivan Li, Yaying Li, Mengshi Li, Liqun Li, Manxia Li, Ya Li, Changxian Li, Wen-Chao Li, Dan-Ni Li, Sunan Li, Zhencong Li, Chunqing Li, Jiong Li, Lai K Li, Yanni Li, Daiyue Li, Bingong Li, Xiujuan Li, Huifang Li, Yongsheng Li, Lingling Li, Chunxue Li, Yunlong Li, Xinhua Li, Jianshuang Li, Juanling Li, Minerva X Li, Xinbin Li, Alexander H Li, Xue-jing Li, Yuling Li, Ding Li, Wendeng Li, Yetian Li, Xianlin Li, Chuangpeng Li, Mingrui Li, Shengze Li, Ming-Yang Li, Linyan Li, Yanjun Li, Jiequn Li, Zhongding Li, Hewei Li, Da-Jin Li, Jiangui Li, Zhengyang Li, Cyril Li, Xinghui Li, Yuefei Li, Xiao-kun Li, Xinyan Li, Yuanhao Li, Xiaoyun Li, Ji-Lin Li, Congcong Li, Yushan Li, Ping'an Li, Juan Li, Weiping Li, Huan Li, Changjiang Li, Chengping Li, G-P Li, He-Zhen Li, Xiaobin Li, Shaoqi Li, Yuehua Li, Yinliang Li, Wen Li, Jinfeng Li, Shiheng Li, Jiangan Li, Hsiao-Fen Li, Yu-Kun Li, Weihai Li, Zhaojin Li, Bingxin Li, Mengjiao Li, Wenjuan Li, Wenyu Li, Tianxiang Li, Chia-Yang Li, Meng-Meng Li, Liangkui Li, Tian-chang Li, Hairong Li, Yahui Li, Su Li, Xi-Xi Li, Wenlei Li, Mei-Lan Li, Wenjun Li, Jiaxin Li, Haiyan Li, Chenguang Li, Ming D Li, Ruyue Li, Xujun Li, Chi-Ming Li, Yi-Ning Li, Xiaolian Li, Dandan Li, Yunan Li, Zechuan Li, Zhijun Li, Jiazhou Li, Sherly X Li, Wanling Li, Ya-Ge Li, Yinyan Li, Qijun Li, Rujia Li, Guangli Li, Lixia Li, Zhiwei Li, Xueshan Li, Yunrui Li, Yuhuang Li, Shanshan Li, Jiangbo Li, Wan-Shan Li, Xiaohan Li, Zhongwen Li, Huijie Li, W W Li, Yalan Li, Yiyang Li, Jing-gao Li, Fengxiang Li, Xuejun Li, Shunwang Li, Nana Li, Chao Li, Yaqing Li, Jingui Li, Bingsheng Li, Yaqiao Li, Huamao Li, Xiankun Li, Jingke Li, Xiaowei Li, Tianyao Li, Junming Li, Jianfang Li, Shubo Li, Qi-Fu Li, Zi-Zhan Li, Hai-Yun Li, Haoran Li, Zhongxian Li, Xiaoliang Li, Xinyuan Li, Maoquan Li, H-J Li, Chumei Li, Zhixiong Li, Shijie Li, Lingyan Li, Zhanquan Li, Wenguo Li, Fangyuan Li, Xuhang Li, Xiaochun Li, Chen-Lu Li, Xinjian Li, Jialun Li, Zilu Li, Rui Li, Xuemin Li, Zezhi Li, Sheng-Fu Li, Xue-Fei Li, Yudong Li, Shanpeng Li, Hongjiang Li, Wei-Na Li, Dong-Run Li, Yunxi Li, Jingyun Li, Binghua Li, Xuyi Li, Hanjun Li, Yunchu Li, Zhengyao Li, Jin-Qiu Li, Qihua Li, Jiaxuan Li, Jinghao Li, Y-Y Li, Xiaofang Li, Tuoping Li, Pengyun Li, Guangjin Li, Lin-Feng Li, Xutong Li, Ranwei Li, Ziqing Li, Kai Li, Keanning Li, Wei-Li Li, Yongjin Li, Shuangxiu Li, Chenhao Li, Ling Li, Weizu Li, Deming Li, Peiqin Li, Xiaodong Li, Nanxing Li, Qihang Li, Jianrong Li, Baoguo Li, Zhehui Li, Chenghao Li, Jiuyi Li, Chun-Xu Li, Luyao Li, Weike Li, Desheng Li, Zhixuan Li, Chuanbao Li, Long-Yan Li, Fuyu Li, Chuzhong Li, M D Li, Lingzhi Li, Yuan-Tao Li, Kening Li, Guilan Li, Wanshi Li, Hengtong Li, Ling-Zhi Li, Yifan Li, Ya-Li Li, Xiao-Sa Li, Songyun Li, Xiaoran Li, Bolun Li, Kunlin Li, Linchuan Li, Jiachen Li, Shu-Qi Li, Haibin Li, Huangbao Li, Zehua Li, Guo-Chun Li, Xinli Li, Mengyuan Li, S Li, Wenqing Li, Wenhua Li, Caiyun Li, Congye Li, Xinrui Li, Dehai Li, Wensheng Li, Qingshang Li, Jiannan Li, Guanbin Li, Hanbin Li, Zhiyi Li, Xing Li, Wanwan Li, Jia Li Li, Zhaoyong Li, SuYun Li, Shiyi Li, Wan-Hong Li, Suchun Li, Mingke Li, Xiaoyuan Li, Huanhuan Li, Yanan Li, Zongfang Li, Jiayan Li, Yang Li, YueQiang Li, Xiangping Li, H-H Li, Jinman Li, BoWen Li, Duoyun Li, Dongdong Li, Yimei Li, Hao Li, Liliang Li, Mengxi Li, Keyuan Li, Zhi-qiang Li, Shaojing Li, S S Li, Yi-Ting Li, Jiangxia Li, Yujie Li, Tong Li, Lihua Li, Yilong Li, Xue-Lian Li, Yan-Li Li, Zhiping Li, Haiming Li, Yansen Li, Gaijie Li, Jingfeng Li, Zhi-Yuan Li, Hai Li, Yuemei Li, Yanli Li, Yuan-Jing Li, Kaibin Li, Xuefeng Li, Wenjie Li, Xiaohu Li, Ruikai Li, Mengjuan Li, Xiao-Hong Li, Yinglin Li, Yaofu Li, Ren-Ke Li, Qiyong Li, Ruixi Li, Yi Li, Baosheng Li, Zhonglian Li, Yujun Li, Mian Li, Dalin Li, Lixi Li, Jin-Xiu Li, Kun Li, Qizhai Li, Jiwen Li, Pengju Li, Peifeng Li, Zhouhua Li, Ai-Jun Li, Qingqin S Li, Honglei Li, Guojin Li, Yueting Li, Xin-Yue Li, Dingchen Li, YaJie Li, Xiaoling Li, Jixuan Li, Yanqing Li, Zijian Li, Zhandong Li, Xuejie Li, Peining Li, Congjiao Li, Meng-Jun Li, Gaizhen Li, Huilin Li, Liang Li, Songtao Li, Fusheng Li, Huafang Li, Dai Li, Meiyue Li, Nianyu Li, Chenlu Li, Keshen Li, Kechun Li, Yuxin Li, X-L Li, Shaoliang Li, Shawn S C Li, Shu-Xin Li, Hong-Zheng Li, Qun Li, Tianye Li, Cuiguang Li, Dongye Li, Zhen Li, Yuan Li, Chunhong Li, F Li, Mengling Li, Kunpeng Li, Jia-Da Li, Zhenghao Li, Chun-Bo Li, Zhantao Li, Baoqing Li, Pu Li, Xinle Li, Xingli Li, Bingkun Li, Nien-Chi Li, Wuguo Li, Tiewei Li, Bing-Hui Li, Rong-Bing Li, Daniel Tian Li, Honggang Li, Jingyong Li, Rong Li, Shikang Li, Wei-Yang Li, Mingkun Li, Binxing Li, Shi-Ying Li, Zixiao Li, Ming Xing Li, Guixin Li, Quanzhang Li, Ming-Xing Li, Marilyn Li, Da-wei Li, Hong-Lian Li, Bei-Bei Li, Shishi Li, Haitong Li, Xiumei Li, Yuli Li, Melody M H Li, Ruibing Li, Qingfang Li, Peibo Li, Qibing Li, Huanjun Li, Heng Li, Wende Li, Chung-Hao Li, Liuzheng Li, Zhanjun Li, Yifei Li, Tianming Li, Chang-Sheng Li, Xiao-Na Li, Tianyou Li, Jipeng Li, Xidan Li, Yixing Li, Chengcheng Li, Yu-Jin Li, Longxuan Li, Baoting Li, Ka Wan Li, Huiyou Li, Shi-Guang Li, Wenxiu Li, Binbin Li, Xinyao Li, Zhuang Li, Yu-Hao Li, Gui-xing Li, Shunle Li, Shilin Li, Niu Li, Siyue Li, Diyan Li, Mengyao Li, Shili Li, Yixuan Li, Shan-Shan Li, Zhuanjian Li, Meiqing Li, Gerard Li, Yuyun Li, Hengyu Li, Zhiqiong Li, Yinhao Li, Zonglin Li, Pik Yi Li, Junying Li, Jingxin Li, Mufan Li, Chun-Lai Li, Defeng Li, Shiya Li, Zu-guo Li, Xin-Zhu Li, Xiao-Jiao Li, Jia-Xin Li, Kuiliang Li, Pindong Li, Hualian Li, Youchen Li, Junhong Li, Li Li, W Y Li, Hanxue Li, Lulu Li, Yi-Heng Li, Xiaoqin Li, L P Li, Runbing Li, Chunmei Li, Mingjun Li, Yuanhua Li, Qiaolian Li, Yanmin Li, Ji-Cheng Li, Jingyi Li, Yuxiang Li, Haolong Li, Hao-Fei Li, Xuanzheng Li, Peng-li Li, Quan Li, Yining Li, Xue-Ying Li, Xiurong Li, Huijuan Li, Haiyu Li, Xu-Zhao Li, Yunze Li, Yanzhong Li, Guohui Li, Kainan Li, Yongzhe Li, Qingfeng Li, Xiaoyan Li, Tianyi Li, Nanlong Li, Ping Li, Xu-Bo Li, Nien-Chen Li, Fangzhou Li, Yue-Chun Li, Jiahui Li, Huiping Li, Kangyuan Li, Biao Li, Yuanchuang Li, Haiying Li, Yunting Li, Xiaoxuan Li, Anyao Li, Qing-Chang Li, Hongliang Li, Shengbiao Li, Hong-Yan Li, Yue-Rui Li, Ruidong Li, Dalei Li, Zongjun Li, Y M Li, Changqing Li, Hanting Li, Dong-Jie Li, Sijie Li, Xiaomin Li, Dengxiong Li, Meilan Li, D C Li, Andrew C Li, Jianye Li, Yi-Shuan J Li, Tinghao Li, Qiuyan Li, Zhouxiang Li, Tingguang Li, Yun-tian Li, Jianliang Li, Xiangyang Li, Guangzhao Li, Chunjie Li, Yixi Li, Shuyu Dan Li, S A Li, Tianfeng Li, Anna Fen-Yau Li, Minghui Li, Jiangfeng Li, Jinjie Li, Liming Li, Jie-Pin Li, Junyi Li, Kaiyi Li, Wenqun Li, Dongtao Li, Fengyuan Li, Guixia Li, Yinan Li, Aoxi Li, Zuo-Lin Li, Chenxi Li, Yuanjing Li, Zhengwei Li, Linqi Li, Bingjue Li, Xixi Li, Binghu Li, Yan-Chun Li, Suiyan Li, Yu-Hang Li, Qiaoqiao Li, Zhenguang Li, Xiaotian Li, Jia-Ru Li, Shuhui Li, Shu-Hong Li, Chun-Xiao Li, Pei-Qin Li, Shuyue Li, Mengying Li, Quan-Zhong Li, Fangyan Li, Tongzheng Li, Yihong Li, Yaxian Li, Duo Li, Dali Li, Zhiming Li, Xuemei Li, Hongxia Li, Yongting Li, Xueting Li, Danyang Li, Zhenjun Li, Ren Li, Tiandong Li, Lanfang Li, Hongye Li, Mingwei Li, Di-Jie Li, Bo Li, Jinliang Li, Wenxin Li, Qiji Li, W J Li, Zhipeng Li, Zhijia Li, Xiaoping Li, Jingtong Li, Linhong Li, Taoyingnan Li, Lucy Li, Lieyou Li, Zhengpeng Li, Xiayu Li, Huabin Li, Mao Li, Baolin Li, Cuilan Li, Yuting Li, Yongchao Li, Xiaobo Li, Xiaoting Li, Ruotai Li, Meijia Li, Shujiao Li, Yaojia Li, Weirong Li, Xiao-Yao Li, Kun-Ping Li, Weihua Li, Shangming Li, Yibo Li, Yaqi Li, Gui-Hua Li, Zhihong Li, Runzhao Li, Yandong Li, Chaowei Li, Xiang-Dong Li, Huiyuan Li, Yuchun Li, Xiufeng Li, Yanxin Li, Yingjun Li, Xiaohuan Li, Ying-Qin Li, Boya Li, Lamei Li, O Li, Fan Li, Jun Z Li, Suheng Li, Joyce Li, Yiheng Li, Taiwen Li, Hui-Ping Li, Xiaorong Li, Junru Li, Zhiqiang Li, Jiangchao Li, Hecheng Li, Changkai Li, Haifeng Li, Yueping Li, Liping Li, Rena Li, Jiangtao Li, Yu-Jui Li, Zhenglong Li, Yajuan Li, Xuanxuan Li, Rui-Jún Eveline Li, Bing-Mei Li, Yunman Li, Chaoqian Li, Shuhua Li, Yu-Cheng Li, Chunying Li, Yirun Li, Haomiao Li, Leipeng Li, Weiheng Li, Qianqian Li, Baizhou Li, Zhengliang Li, YiQing Li, Han-Ru Li, Sheng Li, Wei-Qin Li, Weijie Li, Yaqiang Li, Guoyin Li, Qingxian Li, Zongyi Li, Dan-Dan Li, Yeshan Li, Qiwei Li, Zirui Li, Yongpeng Li, Keke Li, Chengjun Li, Jianbin Li, Chanyuan Li, Shiying Li, Jianxiong Li, Huaying Li, Ji Li, Tuojian Li, Yixin Li, Ziyue Li, Juntong Li, Zhongzhe Li, Xiang Li, Yumei Li, Xiang-Ping Li, Chaonan Li, Wenqiang Li, Yu-Chia Li, Pei-Shan Li, Zaibo Li, Heying Li, Shaomin Li, Guangming Li, Xuan-Ling Li, Yuxuan Li, Bingshan Li, Xiaoqiang Li, Jiahao Li, Hanxiao Li, Jiansheng Li, Shibao Li, Shuying Li, Pengjie Li, Xiaomei Li, Ruijin Li, Kunlong Li
articles
Shawn C Chafe, Kui Zhai, Nikoo Aghaei +37 more · 2025 · Science translational medicine · Science · added 2026-04-24
Brain metastasis occurs in up to 40% of patients with non-small cell lung cancer (NSCLC). Considerable genomic heterogeneity exists between the primary lung tumor and respective brain metastasis; howe Show more
Brain metastasis occurs in up to 40% of patients with non-small cell lung cancer (NSCLC). Considerable genomic heterogeneity exists between the primary lung tumor and respective brain metastasis; however, the identity of the genes capable of driving brain metastasis is incompletely understood. Here, we carried out an in vivo genome-wide CRISPR activation screen to identify molecular drivers of brain metastasis from an orthotopic xenograft model derived from a patient with NSCLC. We found that activating expression of the Alzheimer's disease-associated beta-secretase 1 (BACE1) led to a substantial increase in brain metastases. Furthermore, genetic and pharmacological inhibition of BACE1 blocked NSCLC brain metastasis. Mechanistically, we identified that BACE1 acts through epidermal growth factor receptor to drive this metastatic phenotype. Together, our data highlight the power of in vivo CRISPR activation screening to unveil molecular drivers and potential therapeutic targets of NSCLC brain metastasis. Show less
📄 PDF DOI: 10.1126/scitranslmed.adu2459
BACE1
Yujiao Zhao, Luyang Ma, Weijun Li +9 more · 2025 · BMC pregnancy and childbirth · BioMed Central · added 2026-04-24
To investigate longitudinal changes in pelvic floor support in primiparous women with pelvic organ prolapse (POP) after vaginal delivery, focusing on single- and multiple-compartment involvement. Two Show more
To investigate longitudinal changes in pelvic floor support in primiparous women with pelvic organ prolapse (POP) after vaginal delivery, focusing on single- and multiple-compartment involvement. Two hundred primiparas after vaginal delivery were prospectively enrolled and underwent pelvic floor MRI at six weeks postpartum. POP was diagnosed and classified into subgroups (single or multiple compartments involved) based on MRI findings. Primiparas with POP underwent repeat MRI at four months postpartum. Pelvic floor measurements, including injury score and functional parameters of the levator ani muscle (puborectal hiatus line, H line; muscular pelvic floor relaxation line, M line; levator hiatus area, LHA; iliococcygeus angle, ICA; levator plate angle, LPA), were assessed on MRI. Measurements were compared among POP subgroups and a normal control group (without POP) at six weeks postpartum. Additionally, changes between six weeks and four months postpartum were analyzed within POP subgroups. Based on MRI criteria, approximately 41.5% of primiparas were diagnosed with POP, predominantly cystoceles commonly associated with uterine prolapse. Functional parameters of the levator ani, except for LPA at rest, were significantly increased in POP subgroups compared to controls. At four months postpartum, M line, H line, and LPA significantly decreased, and prolapsed organs were elevated in cases with multiple compartments involved, compared to six weeks postpartum. No significant changes were observed in cases with single-compartment involvement during follow-up. A substantial proportion of primiparas experienced postpartum POP. Impaired levator ani function contributed to POP. Pelvic floor support improved during early postpartum in cases with multiple-compartment involvement. Show less
📄 PDF DOI: 10.1186/s12884-025-08044-7
LPA
Meng Wang, Zhao Liu, Shuxun Ren +16 more · 2025 · Theranostics · added 2026-04-24
📄 PDF DOI: 10.7150/thno.105894
BCKDK
Ziling Huang, Leyao Li, Xu Cai +3 more · 2025 · Thoracic cancer · Blackwell Publishing · added 2026-04-24
Fibroblast Growth Factor (FGF) ligands and their receptor have been identified as the potent target in non-small cell lung cancer (NSCLC). However, the clinicopathological and microenvironmental chara Show more
Fibroblast Growth Factor (FGF) ligands and their receptor have been identified as the potent target in non-small cell lung cancer (NSCLC). However, the clinicopathological and microenvironmental characteristics of FGF/FGFR in NSCLC remain poorly elucidated. Here, we summarize 4656 NSCLCs and analyze clinicopathological features in 478 FGF/FGFR altered cases. AI analysis and multiplex immunofluorescence staining are used to reveal microenvironment features. First, around 10.27% NSCLC carry FGF/FGFR variant. Squamous cell carcinoma (41.95%) is much more than adenocarcinoma (8.32%). In 118 pathogenic variant (PV) cases, the most frequent variant is FGF/FGFR copy number increase (83.05%), the second is FGFR gene fusion (11.86%). Surprisingly, CCND1 always co-amplifies with FGF19 (100.00%). Furthermore, FGF PV is an independent risk factor for poor outcomes (overall survival: HR = 3.781, disease-free survival: HR = 3.340). And one-third of FGFR3-TACC3 fusion cases show clear cytoplasm in histology. Either CCND1/FGF19 co-amplification or KRAS co-mutation is closely related to cigarette exposure, and KRAS co-mutation acts as an independent factor of poor prognosis. Finally, the FGF/FGFR1/NOTCH1 within RB1 variant group has a remarkably high ratio of inner-tumor CD8+ T cell infiltration, non-exhausted T cells, exhausted T Show less
📄 PDF DOI: 10.1111/1759-7714.70016
FGFR1
Xinyue Yang, Shufen Li, Yuqing Feng +3 more · 2025 · Carbohydrate polymers · Elsevier · added 2026-04-24
Metabolic associated fatty liver disease (MAFLD) is a globally recognized chronic metabolic disorder characterized by lipid metabolism abnormalities. Accumulating evidence indicates that exopolysaccha Show more
Metabolic associated fatty liver disease (MAFLD) is a globally recognized chronic metabolic disorder characterized by lipid metabolism abnormalities. Accumulating evidence indicates that exopolysaccharides (EPS) could modulate the gut microbiota structure and function to prevent and treat MAFLD. Herein, a novel EPS designated BVP1 was isolated from Bacillus velezensis CGMCC 24752. Structural analysis revealed that BVP1 is a neutral α-mannan consisting of a backbone of 1,2,6-linked α-D-Manp, with branches composed of T-linked α-D-Manp, 1,2-linked α-D-Manp, and 1,3-linked α-D-Manp. Animal experiments showed that BVP1 significantly alleviated hepatic steatosis, liver injury and inflammation, and enhanced antioxidant activity in MAFLD mice. Single-nucleus RNA sequencing analysis revealed that BVP1 could restore HFD-induced imbalances in liver sinusoidal endothelial cells, hepatic stellate cells, macrophages and Kupffer cells by upregulating the expression of the lipid degradation gene Cps1 and downregulating the expression of the lipid synthesis gene Acsl1 in these cell subpopulations. Interestingly, BVP1 reshaped the gut microbiota and fecal metabolite profile by enriching beneficial bacteria and associated metabolites including salicylic acid, spermidine, and 4-hydroxyphenyl acetate. Fecal microbiota transplantation experiments verified that the anti-MAFLD effects are mediated by the BVP1-modified gut microbiota. Our findings highlight the potential of BVP1 as a promising therapeutic agent for MAFLD treatment. Show less
no PDF DOI: 10.1016/j.carbpol.2025.124150
CPS1
Da-Ao Nie, Jiangkun Yu, Wenshan Huang +3 more · 2025 · Molecular immunology · Elsevier · added 2026-04-24
As resident immune surveillance cells within the central nervous system (CNS), microglia exert pivotal biological functions in maintaining CNS homeostasis through dynamic modulation of their prolifera Show more
As resident immune surveillance cells within the central nervous system (CNS), microglia exert pivotal biological functions in maintaining CNS homeostasis through dynamic modulation of their proliferative capacity, chemotactic motility, efferocytosis activity, and biphasic secretory mechanisms involving both neuromodulatory factors and pro-inflammatory mediators. These specialized macrophages not only serve as the first line of defense in innate immunity but also orchestrate the regulation of adaptive immune responses; whose functional status directly governs both the physiological integrity of neural circuits and the progression of pathological outcomes. Notably, in neurodegenerative disease models, microglial functional states exhibit pronounced heterogeneity and are tightly regulated by microenvironmental cues. Upon encountering sustained hyperactivation or functional impairment, these cells precipitate a cascade of deleterious events within the neurovascular unit. Building upon these pathophysiological mechanisms, targeted modulation of microglial polarization equilibrium has emerged as a pivotal research focus in developing innovative neuroprotective therapeutic strategies. This review systematically integrates empirical evidence derived from cutting-edge methodologies-including molecular imaging, single-cell multi-omics profiling, and conditional genetic ablation-to mechanistically dissect the dual regulatory roles of microglia in orchestrating neural homeostatic maintenance and driving pathological progression in neurological disorders. Show less
no PDF DOI: 10.1016/j.molimm.2025.07.014
IL27
Teng Wu, Tongsheng Huang, Honglin Ren +26 more · 2025 · Circulation research · added 2026-04-24
Individuals with diabetes are susceptible to cardiac dysfunction and heart failure, potentially resulting in mortality. Metabolic disorders frequently occur in patients with diabetes, and diabetes usu Show more
Individuals with diabetes are susceptible to cardiac dysfunction and heart failure, potentially resulting in mortality. Metabolic disorders frequently occur in patients with diabetes, and diabetes usually leads to remodeling of heart structure and cardiac dysfunction. However, the contribution and underlying mechanisms of metabolic and structural coupling in diabetic cardiac dysfunction remain elusive. Two mouse models of type 2 diabetes (T2DM) were used to assess alterations in glucose/lipid metabolism and cardiac structure. The potential metabolic-structural coupling molecule ACBP (acyl-coenzyme A-binding protein) was screened from 4 published datasets of T2DM-associated heart disease. In vivo loss-of-function and gain-of-function approaches were used to investigate the role of ACBP in diabetic cardiac dysfunction. The underlying mechanisms of metabolic and structural coupling were investigated by stable-isotope tracing metabolomics, coimmunoprecipitation coupled with mass spectrometry, and chromatin immunoprecipitation sequencing. Diabetic mouse hearts exhibit enhanced lipid metabolism and impaired ultrastructure with marked cardiac systolic and diastolic dysfunction. Analysis of 4 T2DM public datasets revealed that Our findings demonstrated that ACBP mediates the bidirectional regulation of cardiomyocyte metabolic and structural associations and identified a promising therapeutic target for ameliorating cardiac dysfunction in patients with T2DM. Show less
no PDF DOI: 10.1161/CIRCRESAHA.124.326044
MYBPC3
Xin Liu, Ting Du, Ruofan Xi +7 more · 2025 · Drug design, development and therapy · added 2026-04-24
Cyclophosphamide (CTX), a cornerstone in breast cancer combination chemotherapy, frequently induces adverse effects including myelosuppression, gastrointestinal disturbances, hepatic impairment, and a Show more
Cyclophosphamide (CTX), a cornerstone in breast cancer combination chemotherapy, frequently induces adverse effects including myelosuppression, gastrointestinal disturbances, hepatic impairment, and alopecia. Chemotherapy-induced alopecia severely impacts patients' quality of life and psychological well-being. Modified Huanjingjian (MHJJ), a traditional Chinese herbal formula, demonstrates clinical efficacy in alleviating chemotherapy-related side effects, yet its mechanisms against CTX-induced alopecia remain uncharacterized. And our main aim was to explore the efficacy and the mechanism of MHJJ in mice. UPLC-QE-Orbitrap-MS characterized MHJJ's chemical composition. A CTX-induced alopecia murine model was established. Systemic toxicity was evaluated through body weight monitoring, automated biochemical analysis (ALT/AST levels), and hematological profiling (WBC/PLT counts). Hair follicle histopathology was assessed via H&E staining. IHC and IF staining quantified proliferation markers and hair follicle stem cell (HFSC) biomarkers. Reduced representation bisulfite sequencing (RRBS) was used to map DNA methylation patterns. Wnt pathway dynamics were analyzed through qRT-PCR and IF staining. We identified 110 bioactive compounds in MHJJ. MHJJ intervention attenuated alopecia severity, restored follicular architecture, and increased follicular density compared to CTX monotherapy (p<0.05). HFSC proliferation markers (Ki67/CD34) showed significant upregulation, while apoptosis markers (Caspase-3) were suppressed. RRBS revealed MHJJ-mediated hypomethylation in differentially methylated regions, with gene body methylation constituting 60% of total methylation changes. Methylation-modulated genes predominantly localized to Wnt signaling pathways: MHJJ enhanced Wnt3/Wnt10a expression while suppressing Cer1/Axin1. Corresponding methylation reductions at promoter and gene body regions were confirmed at mRNA and protein levels. MHJJ mitigates CTX-induced alopecia through epigenetic regulation of HFSCs, specifically via DNA hypomethylation-mediated activation of Wnt3/Wnt10a and suppression of Cer1/Axin1. This mechanism promotes follicular regeneration by restoring Wnt signaling homeostasis, positioning MHJJ as a promising adjuvant for chemotherapy-induced alopecia management. Show less
📄 PDF DOI: 10.2147/DDDT.S523809
AXIN1
Ni Wang, Yanan Xu, Jiahui Li +7 more · 2025 · Journal of microbiology and biotechnology · added 2026-04-24
As a chronic lipid driven arterial disease, dyslipidemia is one of the most critical risk factors for atherosclerosis (AS). The gut microbiota plays an important role in regulating host lipid metaboli Show more
As a chronic lipid driven arterial disease, dyslipidemia is one of the most critical risk factors for atherosclerosis (AS). The gut microbiota plays an important role in regulating host lipid metabolism disorders. Studies have shown that the herb "Gualou-Xiebai" (GLXB) can effectively regulate the blood lipid levels of ApoE Show less
📄 PDF DOI: 10.4014/jmb.2510.10023
APOE
Yicun Li, Yun Wu, Xiaolian Li +4 more · 2025 · Scientific reports · Nature · added 2026-04-24
Head and neck squamous cell carcinoma (HNSCC) poses a global health challenge. The management of HNSCC is complicated by the difficulty in detecting occult lymph node metastases, leading to dilemmas i Show more
Head and neck squamous cell carcinoma (HNSCC) poses a global health challenge. The management of HNSCC is complicated by the difficulty in detecting occult lymph node metastases, leading to dilemmas in elective neck dissection decisions, which will impair patients' quality of life without improving survival for nodal negative patients. We conducted a comparative analysis of the clinical features, genomic alterations, gene expression and methylation, tumor microenvironment and cellular states between the clinically N0 and pathologically N0 (cN0-pN0) patients and occult lymph node metastatic patients. Patients with occult lymph node metastases typically present with more poorly differentiated primary tumors and higher rates of angiolymphatic and perineural invasion. We identified a distinctive genomic mutation spectrum in the primary tumors of patients with occult metastases, notably in genes such as NSD1, ARHGAP15 and SMARCA4. A whole-genome DNA hypomethylation and altered gene expression profiles are identified in occult lymph node metastatic patients. Analysis of the tumor microenvironment revealed an enrichment of CARNS1 + NK cells and CBX1 + tumor cells in occult metastatic patients. In conclusion, patients with occult lymph node metastases exhibit distinct molecular and clinical features compared with cN0-pN0 patients. Show less
📄 PDF DOI: 10.1038/s41598-025-10320-7
CBX1
Xiaobin Mai, Le Wang, Juan Tu +13 more · 2025 · Genes & diseases · Elsevier · added 2026-04-24
📄 PDF DOI: 10.1016/j.gendis.2025.101681
ANGPTL4
Hui Yan, Rui Wang, Suryavathi Viswanadhapalli +35 more · 2025 · Science advances · Science · added 2026-04-24
B cells express many protein ligands, yet their regulatory functions are incompletely understood. We profiled ligand expression across murine B sublineage cells, including those activated by defined r Show more
B cells express many protein ligands, yet their regulatory functions are incompletely understood. We profiled ligand expression across murine B sublineage cells, including those activated by defined receptor signals, and assessed their regulatory capacities and specificities through in silico analysis of ligand-receptor interactions. Consequently, we identified a B cell subset that expressed cytokine interleukin-27 (IL-27) and chemokine CXCL10. Through the IL-27-IL-27 receptor interaction, these IL-27/CXCL10-producing B cells targeted CD40-activated B cells in vitro and, upon induction by immunization and viral infection, optimized antibody responses and antiviral immunity in vivo. Also present in breast cancer tumors and retained there through CXCL10-CXCR3 interaction-mediated self-targeting, these cells promoted B cell PD-L1 expression and immune evasion. Mechanistically, Show less
📄 PDF DOI: 10.1126/sciadv.adx9917
IL27
Fiza Javed, Robert A Hegele, Abhimanyu Garg +6 more · 2025 · Journal of clinical lipidology · Elsevier · added 2026-04-24
Familial chylomicronemia syndrome (FCS) is a rare Mendelian autosomal recessive disorder (MIM 238600) characterized by extreme and sustained hypertriglyceridemia due to profound reduction of lipoprote Show more
Familial chylomicronemia syndrome (FCS) is a rare Mendelian autosomal recessive disorder (MIM 238600) characterized by extreme and sustained hypertriglyceridemia due to profound reduction of lipoprotein lipase (LPL) activity. This expert opinion statement synthesizes current knowledge on the definition, pathophysiology, genetics, prevalence, diagnosis, and management of FCS. FCS typically manifests at a young age with persistent severe hypertriglyceridemia-defined as ≥10 mmol/L (≥885 mg/dL), or ≥1000 mg/dL (≥11.2 mmol/L) depending on region and whether Systeme International (SI) units are utilized-in the absence of secondary factors, resistance to conventional lipid-lowering therapies, and a high lifetime risk of acute pancreatitis. It is caused by biallelic pathogenic variants in the LPL gene encoding LPL, or 1 of 4 other related genes that encode proteins that interact with LPL. Affected individuals require a strict, lifelong very low-fat diet with <15% of energy from fat. Emerging therapies inhibiting apolipoprotein C-III show promise in reducing serum triglycerides and pancreatitis risk in patients with FCS. A multidisciplinary approach, encompassing dietary management, pharmacotherapy, and patient education, is pivotal in mitigating the significant morbidity associated with FCS. Show less
no PDF DOI: 10.1016/j.jacl.2025.03.013
LPL
Hongzhi Li, Guangming Li, Xian Gao +4 more · 2025 · Scientific reports · Nature · added 2026-04-24
Cellular senescence is a hallmark for cancers, particularly in lung adenocarcinoma (LUAD). This study developed a risk model using senescence signature genes for LUAD patients. Based on the RNA-seq, c Show more
Cellular senescence is a hallmark for cancers, particularly in lung adenocarcinoma (LUAD). This study developed a risk model using senescence signature genes for LUAD patients. Based on the RNA-seq, clinical information and mutation data of LUAD patients collected from the TCGA and GEO database, we obtained 102 endotheliocyte senescence-related genes. The "ConsensusClusterPlus" R package was employed for unsupervised cluster analysis, and the "limma" was used for the differentially expressed gene (DEG) analysis. A prognosis model was created by univariate and multivariate Cox regression analysis combined with Lasso regression utilizing the "survival" and "glmnet" packages. KM survival and receiver operator characteristic curve analyses were conducted applying the "survival" and "timeROC" packages. "MCPcounter" package was used for immune infiltration analysis. Immunotherapy response analysis was performed based on the IMvigor210 and GSE78220 cohort, and drug sensitivity was predicted by the "pRRophetic" package. Cell invasion and migration were tested by carrying out Transwell and wound healing assays. According to the results, a total of 32 genes related to endotheliocyte senescence were screened to assign patients into C1 and C2 subtypes. The C2 subtype showed a significantly worse prognosis and an overall higher somatic mutation frequency, which was associated with increased activation of cancer pathways, including Myc_targets2 and angiogenesis. Then, based on the DEGs between the two subtypes, we constructed a five-gene RiskScore model with a strong classification effectiveness for short- and long-term OS prediction. High- and low-risk groups of LUAD patients were classified by the RiskScore. High-risk patients, characterized by lower immune infiltration, had poorer outcomes in both training and validation datasets. The RiskScore was associated with the immunotherapy response in LUAD. Finally, we found that potential drugs such as Cisplatin can benefit high-risk LUAD patients. In-vitro experiments demonstrated that silencing of Angiopoietin-like 4 (ANGPTL4), Gap Junction Protein Beta 3 (GJB3), Family with sequence similarity 83-member A (FAM83A), and Anillin (ANLN) reduced the number of invasive cells and the wound healing rate, while silencing of solute carrier family 34 member 2 (SLC34A2) had the opposite effect. This study, collectively speaking, developed a prognosis model with senescence signature genes to facilitate the diagnosis and treatment of LUAD. Show less
📄 PDF DOI: 10.1038/s41598-025-95551-4
ANGPTL4
Ping Huang, Yong Zhao, Haiyan Wei +8 more · 2025 · International journal of chronic obstructive pulmonary disease · added 2026-04-24
In preliminary research and literature review, we identified a potential link between chronic obstructive pulmonary disease (COPD) and lipid metabolism. Therefore, this study employed Mendelian random Show more
In preliminary research and literature review, we identified a potential link between chronic obstructive pulmonary disease (COPD) and lipid metabolism. Therefore, this study employed Mendelian randomization (MR) analysis to investigate the potential causal connection between blood lipids and COPD. A genome-wide association study (GWAS) on COPD was conducted, encompassing a total of 112,583 European participants from the MRC-IEU. Additionally, extensive UK Biobank data pertaining to blood lipid profiles within European cohorts included measurements for low-density lipoprotein cholesterol (LDL-C) with 440,546 individuals, high-density lipoprotein cholesterol (HDL-C) with 403,943 individuals, triglycerides (TG) with 441,016 individuals, total cholesterol (TC) with 187,365 individuals, apolipoprotein A-I (apoA-I) with 393,193 individuals, and apolipoprotein B (apoB) with 439,214 individuals. Then, MR analyses were performed for lipids and COPD, respectively. The primary analytical technique employed was the inverse-variance weighted (IVW) approach, which included a 95% confidence interval (CI) to calculate the odds ratio (OR). Additionally, a sensitivity analysis was conducted to assess the dependability of the MR analysis outcomes. MR analysis was primarily based on IVW, unveiled a causal link between COPD and LDL-C (OR=0.994, 95% CI (0.989, 0.999), P=0.019), TG (OR=1.005, 95% CI (1.002, 1.009), P=0.006), and apoA-I (OR=0.995, 95% CI (0.992, 0.999), P=0.008), in addition, no causal link was found with HDL-C, TC, apoB. Sensitivity analysis demonstrated the robustness of these causal relationships. However, through multivariate MR(MVMR) and multiple testing correction, LDL-C and TG had no causal effect on the outcome. ApoA-I remained a protective factor for the risk of COPD (OR=0.994, 95% CI (0.990-0.999), P=0.008). Through MR analysis, this study offers evidence of a causal link between apoA-I with COPD. This further substantiates the potential role of lipid metabolism in COPD, and has significant clinical implications for the prevention and management of COPD. Show less
📄 PDF DOI: 10.2147/COPD.S476833
APOB
Lu Wang, Xiao-Yong Xie, Qiu-Ling Pan +13 more · 2025 · Nature communications · Nature · added 2026-04-24
Biomolecular condensates, membrane-less assemblies formed by phase separation, are implicated in neurodegenerative disease, but their role in Alzheimer's disease (AD) remains unclear. Here, we report Show more
Biomolecular condensates, membrane-less assemblies formed by phase separation, are implicated in neurodegenerative disease, but their role in Alzheimer's disease (AD) remains unclear. Here, we report that in the brain of AD patients and animal models, an elevation of poly(C)-binding protein 2 (PCBP2) correlates with biomolecular condensation that involves phase separation. These condensates sequester large numbers of mitochondrial and mRNA-binding proteins, leading to the outside impairment of mitochondrial morphology and function, and BACE1 mRNA decay relative to amyloid deposition. We then identify a small molecule CN-0928 that inhibits the condensates by reducing PCBP2 protein level and mitigates AD pathology and cognitive decline, in which CN-0928 binding to a target protein integrator complex subunit 1 (INTS1) allows to regulate PCBP2 expression. Our findings place PCBP2 condensates as a key player that cooperates the seemingly disparate but important pathways, and show pharmacological modulation of PCBP2 as an effective approach for treating AD. Show less
📄 PDF DOI: 10.1038/s41467-025-65547-9
BACE1
Xiao Li, Xianglong Huang, Keyan Song +5 more · 2025 · Phytomedicine : international journal of phytotherapy and phytopharmacology · Elsevier · added 2026-04-24
Atherosclerosis is the leading cause of cardiovascular disease-related morbidity and mortality. The traditional Chinese medicine Qingre Sanjie Formula (QRSJF), composed of Prunellae Spica, Sargassum, Show more
Atherosclerosis is the leading cause of cardiovascular disease-related morbidity and mortality. The traditional Chinese medicine Qingre Sanjie Formula (QRSJF), composed of Prunellae Spica, Sargassum, Fritillariae Thunbergii Bulbus, Leonuri Herba, and Forsythiae Fructus, has shown efficacy in treating cardiovascular diseases, although its mechanisms are unclear. This study aimed to explore the protective effects of QRSJF against atherosclerosis and the mechanisms involved. The composition of QRSJF was analyzed using Ultra Performance Liquid Chromatography Quadrupole Time-of-Flight Mass Spectrometry. An 8-week high-fat diet (HFD)-induced atherosclerosis model was established in ApoE Both low- and high-dose QRSJF effectively attenuated dyslipidemia and decreased serum inflammatory cytokine levels in HFD-fed ApoE QRSJF improves dyslipidemia and reduces atherosclerotic plaque in ApoE Show less
no PDF DOI: 10.1016/j.phymed.2025.156691
NR1H3
Maoxia Fan, Na Li, Libin Huang +3 more · 2025 · Cardiovascular therapeutics · added 2026-04-24
📄 PDF DOI: 10.1155/cdr/5711316
ANGPTL4
Kang-Chih Fan, Szu-Chi Chen, I-Weng Yen +7 more · 2025 · Archives of medical science : AMS · added 2026-04-24
Angiopoietin-like protein 4 (ANGPTL4) is a hepatokine implicated in fat metabolism regulation. Its genetic inactivation has been associated with improved glucose homeostasis, while elevated plasma ANG Show more
Angiopoietin-like protein 4 (ANGPTL4) is a hepatokine implicated in fat metabolism regulation. Its genetic inactivation has been associated with improved glucose homeostasis, while elevated plasma ANGPTL4 levels are observed in diabetic and obese individuals. However, the potential link between ANGPTL4 and diabetes- or obesity-related complications remains uncertain. This study aimed to explore whether plasma ANGPTL4 level could serve as a predictor of cancer mortality, cardiovascular mortality, and all-cause mortality in a community-based cohort. A community-based cohort study was conducted, where fasting plasma ANGPTL4 concentrations were measured at baseline, and vital status was ascertained through linkage with the National Health Insurance Research Database in Taiwan. During a 10.46-year follow-up period, 29 (2.49%) of the 1163 participants died. Subjects within the highest tertile of plasma ANGPTL4 levels exhibited the lowest survival rate. In unadjusted models, plasma ANGPTL4 significantly predicted all-cause mortality, cancer mortality, and cardiovascular or cancer-related mortality. Upon adjustment for confounders including age, sex, smoking, body mass index (BMI), hypertension, diabetes mellitus (DM), and renal function, each standard deviation increase in plasma ANGPTL4 was associated with HRs of 1.35 (95% CI: 1.01-1.80, Plasma ANGPTL4 emerges as a promising biomarker capable of predicting 10-year mortality and enhancing risk prediction beyond established risk factors. Show less
📄 PDF DOI: 10.5114/aoms/189504
ANGPTL4
Zheyi Wang, Yize Sun, Zetai Bai +3 more · 2025 · Movement disorders : official journal of the Movement Disorder Society · Wiley · added 2026-04-24
Mitochondrial dysfunction is increasingly recognized as a key factor in neurodegenerative diseases (NDDs), underscoring the therapeutic potential of targeting mitochondria-related genes. This study ai Show more
Mitochondrial dysfunction is increasingly recognized as a key factor in neurodegenerative diseases (NDDs), underscoring the therapeutic potential of targeting mitochondria-related genes. This study aimed to identify novel biomarkers and drug targets for these diseases through a comprehensive analysis that integrated genome-wide Mendelian randomization (MR) with genes associated with mitochondrial function. Using existing publicly available genome-wide association studies (GWAS) summary statistics and comprehensive data on 1136 mitochondria-related genes, we initially identified a subset of genes related to mitochondrial function that exhibited significant associations with NDDs. We then conducted colocalization and summary-data-based Mendelian randomization (SMR) analyses using expression quantitative trait loci (eQTL) to validate the causal role of these candidate genes. Additionally, we assessed the druggability of the encoded proteins to prioritize potential therapeutic targets for further exploration. Genetically predicted levels of 10 genes were found to be significantly associated with the risk of NDDs. Elevated DMPK and LACTB2 levels were associated with increased Alzheimer's disease risk. Higher expression of NDUFAF2, BCKDK, and MALSU1, along with lower TTC19, raised Parkinson's disease risk. Higher ACLY levels were associated with both amyotrophic lateral sclerosis and multiple sclerosis (MS) risks, while decreased MCL1, TOP3A, and VWA8 levels raised MS risk. These genes primarily impact mitochondrial function and energy metabolism. Notably, several druggable protein targets identified are being explored for potential NDDs treatment. This data-driven MR study demonstrated the causal role of mitochondrial dysfunction in NDDs. Additionally, this study identified candidate genes that could serve as potential pharmacological targets for the prevention and treatment of NDDs. © 2025 International Parkinson and Movement Disorder Society. Show less
no PDF DOI: 10.1002/mds.30123
BCKDK
Yuping Huang, Junguang Liao, Panpan Shen +7 more · 2025 · JCI insight · added 2026-04-24
Cranial neural crest cells (CNCs) play a critical role in craniofacial bone morphogenesis, engaging in intricate interactions with various molecular signals to ensure proper development, yet the molec Show more
Cranial neural crest cells (CNCs) play a critical role in craniofacial bone morphogenesis, engaging in intricate interactions with various molecular signals to ensure proper development, yet the molecular scaffolds coordinating these processes remain incompletely defined. Here, we identify neurofibromin 2 (Nf2) as a critical regulator to direct CNC-derived skull morphogenesis. Genetic ablation of Nf2 in murine CNCs causes severe craniofacial anomalies, featuring declined proliferation and increased apoptosis in osteoprogenitors, impaired type I collagen biosynthesis and trafficking, and aberrant osteogenic mineralization. Mechanistically, we uncover that Nf2 serves as a molecular linker that individually interacts with FGF receptor 1 (FGFR1) and Akt through spatially segregated phosphor-sites, and structural modeling and mutagenesis identified Ser10 and Thr230 as essential residues, with Thr230 mutation selectively ablating Akt binding while preserving FGFR1 association. Strikingly, Akt inhibition phenocopied Nf2 deficiency, reducing collagen production and Nf2 phosphorylation, whereas phospho-mimetic Nf2 (T230D) rescued CNC-derived osteogenic defects in Nf2-mutant animals. Our findings underscore the physiological significance of Nf2 as a phosphorylation-operated scaffold licensing the FGFR1/AKT axis to regulate collagen type I biogenesis and trafficking, ensuring normal CNC-derived osteogenesis and craniofacial bone development, thus exposing the Nf2/FGFR1/AKT signaling axis as a therapeutic target and promising advancements in treatment of craniofacial anomalies. Show less
📄 PDF DOI: 10.1172/jci.insight.191112
FGFR1
Chenwen Li, Yidan Chen, Yuan Li +9 more · 2025 · Acta pharmaceutica Sinica. B · Elsevier · added 2026-04-24
Accumulating evidence has demonstrated that nucleic acid-based therapies are promising for atherosclerosis. However, nearly all nucleic acid delivery systems developed for atherosclerosis necessitate Show more
Accumulating evidence has demonstrated that nucleic acid-based therapies are promising for atherosclerosis. However, nearly all nucleic acid delivery systems developed for atherosclerosis necessitate injection, which results in rapid elimination and poor patient compliance. Consequently, oral delivery strategies capable of targeting atherosclerotic plaques are imperative for nucleic acid therapeutics. Herein we report the development of yeast-derived capsules (YCs) packaging an antisense oligonucleotide (AM33) targeting microRNA-33 (miR-33) for the oral treatment of atherosclerosis. YCs provide stability for AM33, preventing its premature release in the gastrointestinal tract. AM33-containing YCs, defined as YAM33, showed high transfection in macrophages, thus promoting cholesterol efflux and inhibiting foam cell formation by regulating the target genes/proteins of miR-33. Orally delivered YAM33 effectively accumulated within atherosclerotic plaques in Show less
📄 PDF DOI: 10.1016/j.apsb.2025.07.039
APOE
Wenxiu Wang, Rui Li, Zimin Song +4 more · 2025 · JAMA cardiology · added 2026-04-24
Despite substantial progress in low-density lipoprotein cholesterol (LDL-C)-lowering strategies, residual cardiovascular risk remains. Apolipoprotein C3 (APOC3) has emerged as a novel target for lower Show more
Despite substantial progress in low-density lipoprotein cholesterol (LDL-C)-lowering strategies, residual cardiovascular risk remains. Apolipoprotein C3 (APOC3) has emerged as a novel target for lowering triglycerides. Multiple clinical trials of small-interfering RNA therapeutics targeting APOC3 are currently underway. To investigate whether genetically predicted lower APOC3 is associated with a reduction in cardiovascular risk and if the combined exposure to APOC3 and LDL-C-lowering variants is associated with a reduction in the risk of coronary heart disease (CHD). This was a population-based genetic association study with 2 × 2 factorial mendelian randomization. Included were participants of European ancestry in the UK Biobank. Data were analyzed from November 2023 to July 2024. Genetic scores were constructed to mimic the effects of APOC3, 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), and proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors. Plasma lipid and lipoprotein levels, CHD, and type 2 diabetes (T2D). This study included 401 548 UK Biobank participants (mean [SD] age, 56.9 [8.0] years; 216 901 female [54.0%]). Genetically predicted lower APOC3 was associated with a lower risk of CHD (odds ratio [OR], 0.96; 95% CI, 0.93-0.98) and T2D (0.97; 95% CI, 0.95-0.99). Genetically lower APOC3 and PCSK9 were associated with a similar magnitude of risk reduction in CHD per 10-mg/dL decrease in apolipoprotein B (ApoB) level (APOC3: 0.70; 95% CI, 0.59-0.83; PCSK9: 0.71; 95% CI, 0.65-0.77). Combined exposure to genetically lower APOC3 and PCSK9 was associated with an additive lower risk of CHD (APOC3: 0.96; 95% CI, 0.92-0.99; PCSK9: 0.93; 95% CI, 0.90-0.97; combined: 0.90; 95% CI, 0.86-0.93). Genetically lower HMGCR was also associated with a lower risk of CHD, and the risk was further reduced when combined with APOC3 (0.93; 95% CI, 0.90-0.97). Genetically predicted lower APOC3 was associated with a reduced risk of CHD that is comparable with that associated with lower PCSK9 per unit decrease in ApoB. Combined exposure to APOC3 and LDL-C-lowering variants was associated with an additive reduction in CHD risk. Future studies are warranted to investigate the therapeutic potential of these combined therapies, particularly among high-risk patients who cannot achieve therapeutic targets with existing lipid-lowering therapies. Show less
no PDF DOI: 10.1001/jamacardio.2025.0195
APOB
Long Xu, Yuanyuan Zhao, Shuxi Song +3 more · 2025 · European journal of medical research · BioMed Central · added 2026-04-24
Lung adenocarcinoma (LUAD) is a major cause of cancer-related morbidity and mortality globally, with challenges in prognosis and treatment due to its complex pathogenesis and heterogeneous tumor micro Show more
Lung adenocarcinoma (LUAD) is a major cause of cancer-related morbidity and mortality globally, with challenges in prognosis and treatment due to its complex pathogenesis and heterogeneous tumor microenvironment (TME). Neutrophil extracellular traps (NETs) and oxidative stress play critical roles in tumor progression: NETs promote tumor cell adhesion, migration, and immune suppression, while oxidative stress induces DNA damage and activates pro-tumor signaling pathways. Moreover, oxidative stress is an important inducer of NETs, and their crosstalk shapes the LUAD immune microenvironment. However, systematic exploration of LUAD immunotherapeutic response prediction based on NETs and oxidative stress-related genes remains lacking. The gene set related to oxidative stress was obtained from MSigDB. The gene set related to NETs was sourced from relevant literature. Transcriptomic and clinical data were integrated from The Cancer Genome Atlas (TCGA)-LUAD (training set) and GSE31210 (validation set). Weighted Gene Co-Expression Network Analysis (WGCNA) was employed to screen gene modules and characteristic scores related to NETs and oxidative stress signatures. Differentially expressed genes (DEGs) were screened, and prognostic model was established using univariate and LASSO Cox regression. Immune infiltration was analyzed using ESTIMATE algorithm, MCP-counter and ssGSEA methods. And we developed a nomogram incorporating clinicopathological features and RiskScore model, and performed drug sensitivity analysis. Finally, the biological role of CPS1 in lung cancer cells was investigated through CCK-8, wound-healing, and Transwell experiments. 22 co-expression modules were screened, among which the brown module showed significant correlations with NETs and oxidative stress signature scores. This module was intersected with DEGs, yielding 624 overlapping genes implicated in immune-relevant pathways (like leukocyte differentiation, neutrophil activation involved in immune response). A prognostic model was established utilizing 8 key genes (ADGRE3, ARHGEF3, CD79A, CLEC7A, CPS1, EPHB2, LARGE2, and OAS3). In the TCGA database, the model demonstrated robust prognostic discrimination (area under the curve (AUC) > 0.6), with high-risk patients exhibiting shorter overall survival (OS) (p < 0.05). Its stability was validated in GSE31210 (AUC > 0.6). The RiskScore showed negative correlations with immune infiltration (like T cells, CD8 T cells, and natural killer cells) as well as immune/stromal scores. A nomogram model combining RiskScore with N staging was developed and validated, demonstrating strong predictive accuracy through calibration and decision curve analyses. High-risk patients were more sensitive to drugs like BI-2536, BMS-509744, and Pyrimethamine. Finally, in vitro tests showed that CPS1 knockdown markedly decreased the viability, migration, and invasion of lung cancer cells. The constructed prognostic model by NETs and oxidative stress-relevant genes effectively predicts LUAD prognosis, correlates with immune microenvironment characteristics, and guides drug sensitivity, providing novel insights for LUAD prognostic assessment and personalized therapy. Show less
📄 PDF DOI: 10.1186/s40001-025-03553-9
CPS1
Xiangyong Kong, Yanchen Cai, Yuwei Li +1 more · 2025 · Health information science and systems · Springer · added 2026-04-24
Atherosclerotic cardiovascular disease (ASCVD) is a major threat to human life and health, and dyslipidemia with elevated low-density lipoprotein cholesterol (LDL-C) is an important risk factor, and i Show more
Atherosclerotic cardiovascular disease (ASCVD) is a major threat to human life and health, and dyslipidemia with elevated low-density lipoprotein cholesterol (LDL-C) is an important risk factor, and in the optimal LDL-C scenario, apolipoprotein B (ApoB) has a more predictive value of ASCVD risk. The study is a genome-wide association study (GWAS) based on a European population. A large GWAS dataset for atherosclerotic cardiovascular diseases was targeted, including coronary heart disease (CHD), ischemic stroke (IS), large-artery atherosclerotic stroke (ISL), small-vessel stroke (ISS), and myocardial infarction (MI). Univariate two-sample mendelian randomization (MR) analyses of ApoB and the above cardiovascular diseases were performed separately, and the association was assessed mainly using the inverse variance weighted (IVW) method, with confidence intervals for the superiority ratios set at 95%. In addition, the experiment was supplemented using MR-Egger, weighted model and weighted median (WM). Based on the results of univariate two-sample mendelian randomisation analysis, it was shown that there was a causal relationship between ApoB and CHD (OR = 1.710, 95% CI 1.529-1.912, P = 0.010), ISL (OR = 1.430, 95% CI 1.231-1.661, P = 2.714E-06), ISS (OR = 1.221, 95% CI 1.062-1.405, P = 0.005) were causally related to each other and the disease prevalence ratio was positively correlated with ApoB concentration. This MR analysis demonstrated a causal relationship between ApoB and CHD, ISL, ISS, but not with the risk of developing IS and MI, which further validated the relationship between ApoB and the risk of ASCVD, and contributed to a better understanding of the genetic impact of ApoB on ASCVD, and to a certain extent, could improve the management of ApoB and reduce the prevalence of ASCVD. Show less
no PDF DOI: 10.1007/s13755-024-00323-5
APOB
Yingying Qiu, Xinjun Wei, Jian Cao +9 more · 2025 · Reproductive sciences (Thousand Oaks, Calif.) · Springer · added 2026-04-24
Adenomyosis (AM), a gynecological disorder that severely affects female reproductive health. AM-associated macrophage (AAM) polarization-induced epithelial-mesenchymal transition (EMT) is a key driver Show more
Adenomyosis (AM), a gynecological disorder that severely affects female reproductive health. AM-associated macrophage (AAM) polarization-induced epithelial-mesenchymal transition (EMT) is a key driver of AM progression. In this study, we investigated the role and underlying mechanisms of endometrial mesenchymal stem cell (eMSC)-derived exosomes in regulating AAM polarization and the subsequent EMT of endometrial epithelial cells (EECs). In vitro coculture studies revealed that AM eutopic eMSCs markedly induced M2 macrophage polarization via exosomes and promoted EMT of EECs. Differentially expressed microRNAs (DE-miRNAs) between exosomes derived from normal eMSCs (N-eMSCs) and AM eutopic eMSCs (A-eMSCs) were identified using miRNA sequencing and miR-4669 was found to be the most significantly upregulated miRNA. Internalization of exosomal miR-4669 by macrophages induced their polarization toward the M2 phenotype and promoted the EMT of EECs. Mechanistic analysis using luciferase assay, mRNA sequencing, and rescue experiments revealed that miR-4669 induced M2 macrophage polarization via downregulation of DUSP6 and activation of MAPK/ERK signaling. The polarized M2 macrophages promoted the EMT of ISK cells via TGF-β1 secretion. In an AM xenograft mouse model, miR-4669 depletion inhibited AM progression by targeting the DUSP6/ERK1/2 pathway in macrophages. Overall, AM A-eMSC-derived exosomal miR-4669 facilitates M2 macrophage polarization by targeting the DUSP6/ERK signaling pathway, thereby promoting EMT of EECs via TGF-β1 secretion. These findings open avenues for developing novel preventive and therapeutic strategies for AM. Show less
📄 PDF DOI: 10.1007/s43032-025-01944-1
DUSP6
Xiaolei Song, Chenchen Wang, Qin Ding +8 more · 2025 · Journal of controlled release : official journal of the Controlled Release Society · Elsevier · added 2026-04-24
Alzheimer's disease (AD) is an irreversible and progressive neurodegenerative disorder. The vicious circle between amyloid-β peptide (Aβ) overgeneration and microglial dysfunction is an important path Show more
Alzheimer's disease (AD) is an irreversible and progressive neurodegenerative disorder. The vicious circle between amyloid-β peptide (Aβ) overgeneration and microglial dysfunction is an important pathological event that promotes AD progression. However, therapeutic strategies toward only Aβ or microglial modulation still have many problems. Herein, inspired by the Aβ transportation, an Aβ-derived peptide (CKLVFFAED) engineered biomimetic nanodelivery system (MK@PC-R NPs) is reported for realizing BBB penetration and reprogram neuron and microglia in AD lesion sites. This hollow mesoporous Prussian blue-based MK@PC-R NPs carrying curcumin and miRNA-124 can down-regulate β secretase expression, thereby inhibiting Aβ production and reducing Aβ-induced neurotoxicity. Meanwhile, MK@PC-R NPs with excellent antioxidant and anti-inflammatory properties could normalize the microglial phenotype and promote Aβ degradation, providing neuroprotection. As expected, after treatment with MK@PC-R NPs, the Aβ burdens, neuron damages, neuroinflammation, and memory deficits of transgenic AD mice (APP/PS1 mice) are significantly attenuated. Overall, this biomimetic nanodelivery system with anti-Aβ and anti-inflammatory properties provides a promising strategy for the multi-target therapy of early AD. Show less
no PDF DOI: 10.1016/j.jconrel.2024.12.060
BACE1
Bo-Yi Pan Lulji Taraqaz, Yu-Ting Hsu, Ping-Hsuan Tsai +4 more · 2025 · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · Elsevier · added 2026-04-24
Dyslipidemia exacerbates pancreatic β-cell apoptosis, heightening the risk of type 2 diabetes (T2DM). Kansuinine A (KA), a diterpene from Euphorbia roots, exhibits antiapoptotic properties, suggestive Show more
Dyslipidemia exacerbates pancreatic β-cell apoptosis, heightening the risk of type 2 diabetes (T2DM). Kansuinine A (KA), a diterpene from Euphorbia roots, exhibits antiapoptotic properties, suggestive of its therapeutic potential against T2DM. In this study, we evaluated the protective effects of KA against apolipoprotein C3 (ApoC3)-rich low-density lipoprotein (LDL) (AC3RL)-induced β-cell apoptosis and its underlying mechanism of action. ApoE Show less
no PDF DOI: 10.1016/j.biopha.2025.118066
APOC3
Ting He, Jinbo Zhao, Ling Hou +2 more · 2025 · International journal of general medicine · added 2026-04-24
Coronary heart disease (CHD) has a significant co-morbid association with chronic kidney disease (CKD), but identification tools for the risk of concomitant CKD in patients with CHD are still lacking. Show more
Coronary heart disease (CHD) has a significant co-morbid association with chronic kidney disease (CKD), but identification tools for the risk of concomitant CKD in patients with CHD are still lacking. The purpose of this research was to construct machine learning (ML) models for identifying undetected CKD in CHD patients. 1786 CHD patients undergoing coronary intervention were retrospectively included. Lasso regression and multifactor logistic regression were used to screen feature variables. Five ML models, ie, logistic regression (LR), support vector machine (SVM), random forest (RF), gradient boosting machine (GBM), and extreme gradient boosting (XGBoost), were constructed. Participants were divided into the training set and validation set in a 7:3 ratio. The evaluation metrics included the area under the curve, calibration curve, and decision curve. Totally, 1786 CHD patients were enrolled and split into training (70%) and validation (30%) sets. The prevalence of CKD was 21.8% (390/1786). Multivariate logistic regression analysis showed that men, advanced age, hypertension, diabetes mellitus, history of atrial fibrillation (AF), high Gensini, low hemoglobin, low plateletcrit (PCT), high triglycerides (TG), high lipoprotein(a) (Lp(a)), hyperkalemia, high uric acid to albumin ratio (UAR), high systemic inflammation response index (SIRI), low lymphocyte to monocyte ratio (LMR), and high apolipoprotein B to apolipoprotein A1 (ApoB/ApoA1) ratio were the key clinical and laboratory test indicators of CKD. The XGBoost model performed optimally in the validation set (AUC=0.909, 95% CI 0.881 -0.937). SHapley Additive explanation analysis identified UAR, hypertension, Gensini score, age, and SIRI as the top 5 key features. The XGBoost model constructed on routine clinical data was effective in identifying CKD risk in CHD patients, with UAR as a novel strong predictor. Decision curve analysis confirmed the clinical utility of the model, indicating that it may be used to guide decisions for enhanced monitoring and early intervention over a wide range of risk thresholds. Show less
📄 PDF DOI: 10.2147/IJGM.S558568
APOB
Lu Shen, Wenqing Zhai, Ping Jiang +6 more · 2025 · American journal of preventive cardiology · Elsevier · added 2026-04-24
Recent researches highlight the interdependence of lipoprotein(a) [Lp(a)] and Lp(a)-associated cardiovascular risk with the background inflammatory burden. This study aimed to investigate whether syst Show more
Recent researches highlight the interdependence of lipoprotein(a) [Lp(a)] and Lp(a)-associated cardiovascular risk with the background inflammatory burden. This study aimed to investigate whether systemic inflammation modulates Lp(a)-associated coronary stenosis in chronic coronary syndromes (CCS). A total of 1513 participants undergoing angiography at a tertiary cardiology center in China were included in our retrospective, cross-sectional study. Participants were categorized into normal, mild, and severe groups based on the Gensini Scores, which quantitatively assess stenosis severity. Multinomial logistic models were calculated according to accompanying systemic inflammation concentration. Participants with elevated Lp(a) levels had a high coronary stenosis risk: fully adjusted model odds ratios (ORs) [95% confidence intervals (CIs)] for the mild vs. normal and severe vs. normal groups were 1.47 (1.11-1.96) and 1.68 (1.21-2.33). Notably, the strongest Lp(a)-coronary stenosis associations after multi-variable adjustment persisted only in low inflammation concentration [systemic inflammation response index (SIRI) < 0.64)] [mild vs. normal, OR 2.03, 95% CI 1.17-3.54, Elevated Lp(a) correlates with coronary stenosis only in low inflammation concentration. Considering systemic inflammation in personalized Lp(a)-lowering therapies is more conducive for CCS managements. Show less
📄 PDF DOI: 10.1016/j.ajpc.2025.101324
LPA